Oral GLP-1 approvals

Weight-loss drugs that were mostly known as shots now have two newly approved pill options in the U.S. (ajmc.com) Glucagon-like peptide-1 drugs mimic a gut hormone that helps people feel full and eat less, and the Food and Drug Administration cleared oral semaglutide for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. The approval letter for Wegovy tablets lists long-term weight reduction and cardiovascular risk reduction indications in those adults. (ajmc.com; accessdata.fda.gov) Novo Nordisk’s oral semaglutide approval was backed by the Phase 3 OASIS 4 trial, which enrolled 307 adults and reported 13.6% mean weight loss at 64 weeks versus 2.2% with placebo. The Food and Drug Administration label also shows Wegovy tablets carry the same boxed warning about thyroid C-cell tumors as injectable semaglutide products. (ajmc.com; accessdata.fda.gov) Eli Lilly added a second pill on April 1, 2026, when the Food and Drug Administration approved Foundayo, the brand name for orforglipron, for adults with obesity or overweight with weight-related medical problems. Lilly said prescriptions were accepted immediately through LillyDirect and shipping began April 6 before a broader retail rollout. (lilly.com; lilly.com) The difference between the two pills is not just the brand name. Lilly says Foundayo can be taken any time of day without food or water restrictions, while oral semaglutide has absorption requirements that have long shaped how patients take the diabetes pill Rybelsus. (lilly.com; accessdata.fda.gov) That convenience is already showing up in early demand. PharmExec, citing Reuters and IQVIA data based on two days of capture ending April 10, reported 1,390 Foundayo prescriptions in the drug’s first week on the market. (pharmexec.com) The new approvals arrive after two years in which injectable obesity drugs strained supply chains, pushed employers and insurers into coverage fights, and spawned telehealth and direct-to-consumer distribution channels. AJMC reported that oral formulations expand choice, but do not automatically lower prices or remove utilization controls. (ajmc.com) Distributors are moving quickly to frame the pill market around access and price. Lilly said Foundayo starts at $25 a month for some commercially insured patients and $149 a month for self-pay, while AJMC reported in January that GoodRx matched Novo Nordisk’s launch pricing for oral semaglutide through its telemedicine service. (lilly.com; ajmc.com) The competitive line is also shifting from injections versus pills to pill versus pill. Lilly said in February that ACHIEVE-3, a head-to-head Phase 3 diabetes trial, showed orforglipron beat oral semaglutide on blood sugar reduction, giving the company an early marketing argument as obesity prescribing expands. (lilly.com) For patients who delayed treatment because they did not want a weekly shot, the market now looks different than it did at the start of 2025. The next fight is likely to center on coverage rules, refill logistics, and whether pill makers can turn easier prescribing into sustained use. (ajmc.com; pharmexec.com)